Related Experiment Video
Updated: Aug 28, 2025

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
Published on: August 28, 2021
Low-dose adjuvant dexmedetomidine did not decrease propofol sedation requirements in children undergoing
Eric G Johnson1,2, Sarah G Weaver3, Kelsey L Batt1
1Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA.
Insights
Adjuvant dexmedetomidine did not reduce propofol dose for pediatric endoscopy. Patients receiving dexmedetomidine experienced more hypotension and longer recovery times post-procedure.
Area of Science:
- Pediatric Anesthesiology
- Gastroenterology
- Pharmacology
Background:
- Propofol is the primary agent for deep sedation during pediatric esophagogastroduodenoscopy (EGD).
- Dexmedetomidine is sometimes used as an adjunct, with potential for propofol-sparing effects.
Purpose of the Study:
- To determine if adding dexmedetomidine to propofol reduces the total propofol dose required for pediatric EGD.
- To assess the impact of adjuvant dexmedetomidine on hemodynamic stability and recovery time.
Main Methods:
- A single-center, retrospective cohort study involving 159 pediatric patients undergoing EGD.
- Patients received either propofol alone (PRO) or dexmedetomidine with propofol (DEX-PRO).
- Propofol dosage, hemodynamic changes, and recovery times were analyzed; multivariable regression identified factors influencing recovery.
Main Results:
- The median propofol dose was similar between the DEX-PRO (0.26 mg/kg/min) and PRO (0.27 mg/kg/min) groups (p=0.730).
- The DEX-PRO group exhibited significantly more post-anesthesia care unit (PACU) hypotension (61% vs. 34%, p=0.001).
- Recovery time was longer in the DEX-PRO group (32.9 min vs. 25.6 min, p<0.001), with age and dexmedetomidine use associated with prolonged recovery.
Conclusions:
- Adjuvant dexmedetomidine does not decrease propofol requirements for pediatric EGD.
- The use of dexmedetomidine in this setting was associated with increased hypotension and extended postoperative recovery.
- Findings suggest caution when using dexmedetomidine as an adjunct for sedation in pediatric EGD due to adverse hemodynamic and recovery outcomes.
Background:
Propofol is the cornerstone of deep sedation during pediatric esophagogastroduodenoscopy (EGD), though adjuvant dexmedetomidine may provide propofol-sparing benefits.
Objective:
The objective of the study was to evaluate whether adjuvant dexmedetomidine decreases the total propofol dose in pediatric patients undergoing EGD.
Methods:
This single-center, retrospective, cohort study evaluated the total propofol dose in pediatric patients undergoing EGD with and without the use of adjuvant dexmedetomidine. Secondary outcomes included the change in hemodynamics across the perioperative continuum and post-procedure recovery time. A multivariable general linear regression was performed to identify associated variables for recovery time post-procedure.
Results:
A total of 159 patients were included in the study; 88 patients received dexmedetomidine and propofol (DEX-PRO), and 71 patients received propofol only (PRO). The median [interquartile range (IQR)] propofol dose in the DEX-PRO group was 0.26 [IQR, 0.17-0.36] mg kg-1 min-1 which was not significantly different than the PRO group at 0.27 [IQR, 0.21-0.34] mg kg-1 min-1 , p = 0.730. Evaluation of secondary end points showed the DEX-PRO group had more cases of post-anesthesia care unit (PACU) hypotension (61% vs. 34%, p = 0.001) and a longer recovery time (32.9 ± 14.1 vs. 25.6 ± 10.8 min, p < 0.001) versus the PRO group, respectively. Multivariable linear regression demonstrated that age and the use of dexmedetomidine were associated with prolonged recovery.
Conclusion:
Adjuvant dexmedetomidine did not reduce propofol requirements compared with propofol alone in pediatric patients undergoing EGD. More hypotension and a longer postoperative recovery time were also seen in patients receiving adjuvant dexmedetomidine for their endoscopic procedure.
Related Concept Videos
Parenteral Anesthetics: Overview
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Stages of General Anesthesia
Skeletal Muscle Relaxants: Therapeutic Uses
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...

